文献速递妇科

新辅助化疗与化疗周期数:一项全国多中心研究

Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study.
PubMed 文献 · Gynecol Oncol · 2017-08-08

该回顾性研究纳入4家加拿大癌症中心的403例ⅡC期和Ⅳ期高级别浆液性癌患者,分析新辅助化疗周期数及巩固化疗周期数对生存的影响。结果显示,接受≥4周期新辅助化疗者预后差于<3周期者(p=0.011),而巩固化疗≥4周期与<3周期相比生存无差异(p=0.33)。

要点

  • 403例接受新辅助化疗的ⅡC期和Ⅳ期高级别浆液性癌患者中,47%达到无残留病灶。
  • 139/403(34.5%)接受≥4周期新辅助化疗,预后差于<3周期者(p=0.011)。
  • 70/403(17.4%)接受≥4周期巩固化疗,与<3周期相比生存无差异(p=0.33)。

核心结论

  • 接受≥4周期新辅助化疗的高级别浆液性癌患者结局差于<3周期者,可能归因于不良预后因素或反应不佳。
  • 巩固化疗周期数对总生存似乎没有影响。

研究设计与样本

  • 回顾性病历审查,使用医疗记录和登记数据库。
  • 在4家加拿大主要癌症中心识别所有接受新辅助化疗的ⅡC期和Ⅳ期高级别浆液性癌患者。
  • 共纳入403例接受新辅助化疗的患者。

主要发现

  • 403例中47%达到无残留病灶。
  • 139/403(34.5%)接受≥4周期新辅助化疗,预后差于<3周期者(p=0.011)。
  • 70/403(17.4%)接受≥4周期巩固化疗,生存无差异(p=0.33)。

关键数值与推荐

  • 新辅助化疗周期按<3周期或≥4周期分组分析。
  • 巩固化疗周期按<3周期或≥4周期分组分析。

临床怎么用

  • 晚期高级别浆液性癌采用手术联合化疗管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Six cycles of consolidation chemotherapy have become the standard for ovarian cancer treatment regimen following primary cytoreduction, yet with neoadjuvant chemotherapy (NAC), only 3 consolidation cycles are used. This study examines the effects of number of chemotherapy cycles in women with ovarian cancer that are being treated with neoadjuvant chemotherapy. In addition, we examined the effect of number of cycles on survival on consolidation and total chemotherapy. METHODS: All patients with stage IIIC and IV high grade serous carcinoma (HGSC) were identified at 4 major Canadian cancer centers treated with NAC. A retrospective chart review was conducted using the medical charts and registry databases. RESULTS: 403 NAC patients were identified. 47% had zero residual disease. Chemotherapy cycles were divided into <3cycles or ≥4cycles for NAC and consolidation treatments and analyzed with multivariate analysis. 139/403 (34.5%) received ≥4cycles of NAC and had a worse prognosis than <3cycles (p=0.011). 70/403 (17.4%) received ≥4cycles of consolidation treatment and there was no difference in survival (p=0.33) CONCLUSION: Women with advanced HGSC are managed with a combination of surgery and chemotherapy. This is a study of a homogenous cohort of patients with stage IIIC or IV high grade serous cancers who received NAC. ≥4cycles of NAC had a worse outcome than <3cycles likely due to poor prognostic factors or poor response. The number of consolidation cycles did not appear to make a difference in overall survival.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Altman AD, McGee J, May T, et al. Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study. Gynecol Oncol. 2017. PMID: 28800940. doi:10.1016/j.ygyno.2017.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。